Research programme: therapeutic antibodies - Masterclone
Latest Information Update: 16 Jun 2011
At a glance
- Originator Masterclone
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 16 Jun 2011 Discontinued - Preclinical for Undefined indication in Europe (Parenteral)
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
- 12 Jul 2007 Preclinical trials in Undefined indication in Europe (Parenteral)